CORT Stock Analysis: Buy, Sell, or Hold?
CORT - Corcept Therapeutics Inc.
$114.49
-3.83 (-3.24%)
▼
5d:
+20.06%
30d:
+29.4%
90d:
+146.11%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Smart Money Accumulation
None View Scanner →
Strength: 4.6/10
Get Alerted When CORT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CORT is 14.9% above its trading range ($99.63). Market expects -15.7% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CORT is 14.9% above its trading range ($99.63). Market expects -15.7% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$231.09
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$143.49
20.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CORT is currently trading at $114.49, which is considered extended relative to its 30-day fair value range of $83.66 to $99.63. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.1) compared to its historical average (40.3). Remarkably, the market is currently pricing in an annual earnings decline of 15.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CORT is in a strong uptrend. Immediate support is located at $90.00, while resistance sits at $122.21. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: CORT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CORT is in a strong uptrend. Immediate support is located at $90.00, while resistance sits at $122.21. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: CORT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$83.66 -
$99.63
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.9%
Protect Your Profits
CORT is technically overbought (RSI 71). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+14.9% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- NEUTRAL: Near Wall St target ($117.75)
Trading Range Analysis
30-Day Trading Range
$83.66 -
$99.63
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$90.00
Resistance Level
$122.21
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.12
Wall Street Target
$117.75
(+2.8%)
Revenue Growth (YoY)
4.9%
Earnings Growth (YoY)
-21.6%
Profit Margin
6.2%
Valuation Discount vs History
-15.7% cheaper
PE vs Historical
24.1 vs 40.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-15.7%
(market-implied from PE analysis)
1-Year Target
$103.04
(-10%)
2-Year Target
$92.74
(-19%)
3-Year Target
$83.46
(-27%)
3-Yr Target (if PE normalizes)
(PE: 24→40)
$139.45
(+22%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.1, Growth: 482.4%)
$386.40
(+238%)
Base:
(SPY PE: 20.7, Growth: 482.4%)
$332.10
(+190%)
Bear:
(PE: 17.6, Growth: 482.4%)
$282.28
(+147%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (114x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Forward PE: 113.64 | Forward EPS (Implied): $1.01
Bull Case
$138.25
(+21%)
Analyst growth 15.0%, PE expands to 119.3
Base Case
$114.49
(0%)
Market implied 0.0%, PE stable at 113.6
Bear Case
$87.58
(-24%)
Severe decline -15.0%, PE contracts to 102.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.1 to 40.3
Stabilization Target:
$191.29
(+67.1%)
PE Expansion Potential:
+67.1%
Share & Embed Analysis
Last updated: August 02, 2026 2:47 PM ET
Data refreshes hourly during market hours. Next update: 3:47 PM
Data refreshes hourly during market hours. Next update: 3:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CORT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
William Guyer
SELL
20000 shares
2026-04-07
Joseph K Belanoff
SELL
26198 shares
2026-03-25
William Guyer
SELL
11767 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
Advanced CORT Option Strategies
Professional options setups generated by AI based on today's CORT price and gamma walls.
